glp 1 cost plus drugs KFF Health Tracking Poll May 2024: The Public's Use and Views of GLP-1 Costly GLP-1 Drugs are Rarely

10.1172/JCI112855 89 MooreB

[DOI] [PMC free article] [PubMed] [Google Scholar] 123.Zhang L., Lin H., Yang X., Shi J., Sheng X., Wang L., Li T., Quan H., Zhai X., Li W

Nauck erhielt Honorare als Mitglied von Advisory Boards fr Beratungsleistungen fr Boehringer Ingelheim, Eli Lilly & Co., Medtronic, MSD, NovoNordisk, Pfizer, Regor, Sun Pharma und Structure Therapeutics (frher ShouTi, Gasherbrum-Programm), des Weiteren Vortragshonorare von Eli Lilly & Co., Menarini/Berlin Chemie, MSD, Medscape, Medical Learning Institute, NovoNordisk und Sanofi und Forschungsfrderungsmittel an seine Institution von MSD

Choosing the right one involves thinking not just about initial weight loss but about long-term tolerability, cost sustainability, and availability

GLP-1R on arcuate nucleus neurons expressing POMC/CART can mediate Liraglutide-induced weight loss (Secher et al., 2014)

North Carolina eliminated GLP-1 coverage beginning October 2025 due to a budget stalemate in the legislature, but coverage was reinstated in December 2025, bringing the total number of states covering GLP-1s for obesity to 13 as of January 2026